This inventor holds 1 USPTO granted patent and 8 published patent applications and 2 EPO patents. Top assignees: Astellas Pharma Gmbh, Kyoto University. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 425 
1 out of 872 
Years Active: 2023
Title: Norihisa Mikami: Innovator in Regulatory T Cell Production
Introduction
Norihisa Mikami is a prominent inventor based in Kyoto, Japan. He has made significant contributions to the field of immunology, particularly in the production of regulatory T cells (Tregs). His innovative work has implications for various therapeutic applications.
Latest Patents
Mikami holds a patent for a compound and method for producing regulatory T cells. The patent describes a novel compound that exhibits CDK8 and/or CDK19 inhibitory activity. This treatment induces Foxp3 expression in T cells, allowing for the in vitro induction of Tregs. The ability to produce Tregs through this method presents exciting possibilities for immunotherapy.
Career Highlights
Throughout his career, Norihisa Mikami has been associated with esteemed institutions such as Kyoto University and Astellas Pharma GmbH. His work in these organizations has allowed him to advance his research and contribute to the scientific community.
Collaborations
Mikami has collaborated with notable colleagues, including Shimon Sakaguchi and Naganari Ohkura. These partnerships have enriched his research and fostered advancements in the field of regulatory T cell production.
Conclusion
Norihisa Mikami's innovative contributions to the production of regulatory T cells highlight his importance in the field of immunology. His work continues to pave the way for future advancements in therapeutic applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile